Flotek's Data Analytics Becomes a Key Revenue Growth Driver
ChampionX CHX is aggressively expanding its data analytics offerings with its Theta Automation & Optimization platform. ChampionX's system blends real-time monitoring with AI for artificial lift optimization, slashing downtime and boosting production efficiency. In particular, ChampionX excels in downhole and production data services.Meanwhile, Baker Hughes BKR provides extensive digital solutions through its Leucipa production management platform, using AI to predict declines and automate workflows. Baker Hughes covers the entire energy lifecycle, from underground to refining, giving it immense scale. Baker Hughes's services are often bundled with larger equipment or contracts.
Shares of Flotek Industries have surged more than 200% in the past year.
Image Source: Zacks Investment Research
From a valuation standpoint, FTK trades at a forward price-to-earnings ratio of around 22.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Flotek Industries' 2025 and 2026 earnings implies a 65% and 35% improvement year over year, respectively.
Image Source: Zacks Investment Research
The stock currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Baker Hughes Company (BKR) : Free Stock Analysis Report
Flotek Industries, Inc. (FTK) : Free Stock Analysis Report
ChampionX Corporation (CHX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Trump Organization Sues Amazon, Walmart, eBay Sellers For Marketing 'Inferior Imitations' Of Trump Merch
Trump Organization has filed a lawsuit against several unnamed merchandise sellers on popular marketplaces for allegedly marketing counterfeit Trump-branded products. What Happened: The Trump Organization, owned by President Donald Trump, has accused multiple online sellers, including retail giants like Walmart Inc. (NYSE:WMT), Inc. (NASDAQ:AMZN), and eBay Inc. (NASDAQ:EBAY), of selling 'inferior imitations' of Trump-branded merchandise, reported Fortune. The lawsuit was filed in a U.S. District Court in Florida on Friday. Around 9,000 Amazon sellers earned nearly $140 million from Trump merchandise sales in the months before the election, per Omnisend data. Trending: 7,000+ investors have joined Timeplast's mission to eliminate microplastics—now it's your turn to The lawsuit accuses the defendants of 'improperly advertising, marketing, and/or selling unauthorized and illegal products infringing upon at least a portion of plaintiffs' Trump trademarks.' The decision by the Trump Organization to sue these sellers has sparked controversy among legal experts due to its choice of a Schedule A case. Schedule A cases have become popular among trademark lawyers as they permit the plaintiff to sue a broad range of defendants without naming specific entities, often bypassing costly filing fees. This approach also grants considerable power to the judge's discretion. Legal experts have voiced concerns that Schedule A's broad grouping of defendants could lead to smaller vendors being penalized similarly to large-scale operations. Sarah Fackrell, an intellectual property law professor at Chicago-Kent College of Law, warned about due process issues and the risk of defendants being "railroaded."Why It Matters: This lawsuit comes at a time when the Trump brand is expanding its global presence. Earlier this month, Trump Media & Technology Group Corp. (NASDAQ:DJT) launched its TV streaming service, Truth+, worldwide. The company also operates the Truth Social social media platform. In June, Donald Trump Jr., the executive vice president of The Trump Organization, defended his father's financial gains from a family-owned cryptocurrency company, stating that "he doesn't touch it." This followed the disclosure of a $57.7 million income from World Liberty Financial. In April, Donald Trump's online store began selling merchandise branded with "Trump 2028," despite the constitutional prohibition on a third term presidency. This move raised eyebrows and sparked debates about the family's future political plans. Read Next: $100k+ in investable assets? Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes – no cost, no obligation. Jeff Bezos-Backed Arrived Homes Hits A Big Sale On Charlotte Property – Investors Earning A 34.7% Return Image via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Trump Organization Sues Amazon, Walmart, eBay Sellers For Marketing 'Inferior Imitations' Of Trump Merch originally appeared on
Yahoo
26 minutes ago
- Yahoo
Prime Medicine Announces Pricing of Public Offering
CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten public offering of 38,000,000 shares of its common stock at a public offering price of $3.30 per share. The underwriters will not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. Prime Medicine has also granted the underwriters a 30-day option to purchase up to an additional 5,700,000 shares of its common stock. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $125.4 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares of common stock in the offering are to be sold by Prime Medicine. The offering is expected to close on or about August 1, 2025, subject to satisfaction of customary closing conditions. TD Cowen and BMO Capital Markets are acting as joint book-running managers for the offering. The shares of common stock are being offered by Prime Medicine pursuant to an effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 3, 2023 and declared effective by the SEC on November 13, 2023 (File No. 333-275321). The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC's website at The final prospectus supplement relating to and describing the final terms of the offering will be filed with the SEC and may be obtained, when available, TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846, or by email at or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 151 West 42nd Street, 32nd Floor, New York, New York 10036, by email at bmoprospectus@ This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Prime Medicine Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Prime Editors are designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications. Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Prime Medicine's beliefs and expectations regarding: the timing and closing of the public offering. The words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'expect,' 'estimate,' 'seek,' 'predict,' 'future,' 'project,' 'potential,' 'continue,' 'target' and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Prime Medicine's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, and any of its subsequent filings with the SEC. In addition, any forward-looking statements represent Prime Medicine's views only as of today and should not be relied upon as representing its views as of any subsequent date. Prime Medicine explicitly disclaims any obligation to update any forward-looking statements subject to any obligations under applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Investor and Media Contacts Gregory DearbornPrime Medicine857-209-0696gdearborn@ Hannah DeresiewiczPrecision 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
26 minutes ago
- Yahoo
URME United and Hangdog Social Announce Q4 Pre-Grand Opening for Expanded Rancho Cucamonga Location
Member-driven social resort concept enters next growth phase ahead of official launch RANCHO CUCAMONGA, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- URME United, a private consortium integrating lifestyle, hospitality, and financial ventures, and its flagship brand Hangdog Social, have announced the pre-grand opening of Hangdog Social's expanded Rancho Cucamonga location, scheduled for early October Social Logo The new venue, an expansion and relocation of the original Hangdog Social concept, will feature 40 different venues and two 20-room BNB accommodations, this family friendly, entertainment mecca is all designed to deliver a member-driven resort experience. In advance of the opening, Hangdog Social has launched a community-driven support campaign on Indiegogo. The campaign offers early supporters the opportunity to secure discounted memberships and branded merchandise as part of the resort's phased rollout. These advance offerings are intended to involve members in the project's development phase while creating a foundation for the resort community before the official opening. 'Rancho Cucamonga is the next chapter in Hangdog Social's vision to build a global network of member-focused resorts,' said Michael Breault, Managing Director of URME United. 'This pre-grand opening period allows our members and early supporters to play an active role in shaping the experience before we officially open our doors.' The Rancho Cucamonga site will be the second Hangdog Social location in a broader expansion plan to develop 31 resorts worldwide over the next several by Hangdog Social About Hangdog Social Hangdog Social is a member-driven social resort concept combining hospitality, entertainment, and community spaces. Designed for those who value unique dining, nightlife, and social experiences, Hangdog Social offers exclusive membership perks across its growing network of resorts. About URME United URME United is a Private Membership Association and Trust Company developing a network of businesses and ventures in hospitality, beverage technology, finance, and digital innovation. Through brands like Hangdog Social, BevTech Global, SPRiZZi Drink Co., and CBF Bank & Trust, URME United is creating a cohesive private ecosystem for its members worldwide. Media Contact:Tyler MorganCMOURME United909 735 7985flashcall2022@ Photos accompanying this announcement are available at: A video accompanying this announcement is available at: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
